Tarlatamab获得FDA批准:塑造癌症治疗的未来"。

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL Annals of Medicine and Surgery Pub Date : 2024-09-10 eCollection Date: 2024-10-01 DOI:10.1097/MS9.0000000000002555
Iqra Alamgir, Unsa Alamgir, Eman Alamgir, Ayaan Ahmed Qureshi, Muhammad Osama Siddiqui, Mohammed Hammad Jaber, Jatin Motwani
{"title":"Tarlatamab获得FDA批准:塑造癌症治疗的未来\"。","authors":"Iqra Alamgir, Unsa Alamgir, Eman Alamgir, Ayaan Ahmed Qureshi, Muhammad Osama Siddiqui, Mohammed Hammad Jaber, Jatin Motwani","doi":"10.1097/MS9.0000000000002555","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444618/pdf/","citationCount":"0","resultStr":"{\"title\":\"'Tarlatamab's FDA approval: shaping the future of cancer therapy'.\",\"authors\":\"Iqra Alamgir, Unsa Alamgir, Eman Alamgir, Ayaan Ahmed Qureshi, Muhammad Osama Siddiqui, Mohammed Hammad Jaber, Jatin Motwani\",\"doi\":\"10.1097/MS9.0000000000002555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8025,\"journal\":{\"name\":\"Annals of Medicine and Surgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444618/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Medicine and Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/MS9.0000000000002555\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000002555","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
'Tarlatamab's FDA approval: shaping the future of cancer therapy'.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Medicine and Surgery
Annals of Medicine and Surgery MEDICINE, GENERAL & INTERNAL-
自引率
5.90%
发文量
1665
期刊最新文献
Coexistence of Cecal duplication cyst and Meckel's diverticulum presenting as intestinal obstruction: a rare case report: Retraction. Bladder transitional cell carcinoma anatomic primary site as a predictor of survival and mortality: a population-based retrospective cohort study. Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran. Bilateral visual loss as the initial presentation of chronic myeloid leukemia: a case report. Unveiling post-COVID-19 Rasmussen's encephalitis: a case report of rare neurological complication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1